The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study. by Saunders, M. I. et al.
Br. J. Cancer (1982)46, 706
THE RADIOSENSITIZER Ro 03-8799 AND THE CONCENTRATIONS
WHICH MAY BE ACHIEVED IN HUMAN TUMOURS: A PRELIMINARY
STUDY
M. I. SAUNDERSa, S. DISCHEa, D. FERMONTa, A. BISHOPa, I. LENOX-SMITHb,
J. G. ALLENb AND S. L. MALCOLMb
From the aMarie Curie Research Wing for Oncology, Regional Radiotherapy Centre, Mount
Vernon Hospital, Northwood, Middlesex HA6 2RN and bRocheProducts Ltd, PO Box 8, Welwyn
Garden City, Herts AL7 3A Y
Received 27 May 1982 Accepted 2 July 1982
Summary.-A new hypoxic cell radiosensitizer, Ro 03-8799, has been administered
i.v. to 2 normal and 6 patient volunteers. Generally in non-necrotic tumours the
concentrations obtained were 3 times greater than in plasma sampled at the same
time. These observations added to the reports concerning toxicology in monkeys and
rats and radiosensitizing efficiency in the laboratory, suggest that Ro 03-8799 may
prove to be a much more effective sensitizer than misonidazole in man.
THE NEUROTOXICITY of misonidazole
(MISO) has limited the total dose of this
radiosensitizing drug which may be given
to patients. A considerable effort is
currently being made to develop new
drugs which will show greater activity
and/or reduced toxicity so that there can
be greater sensitization ofhypoxic cells in
human tumours.
Nitroimidazoles which have a lower
lipophilicity than MISO are being investi-
gated because they have the promise of a
shorter half-life in plasma and a reduced
uptake in the central nervous system
compared with MISO. Unfortunately, the
first of these compounds to be tested
clinically, desmethylmisonidazole, has
generated an incidence of peripheral
neuropathy similar to that of MISO
(Dische et al., 1981a).
A further area of research is in the
synthesis oflipophilic nitroimidazoles con-
taining a basic side chain. These might be
expected to show both an increased
penetration into tissues, including tum-
ours and a shortened half-life (Smithen et
al., 1980). There is the further possibility
that such compounds maybe concentrated
in areas oflow pH such as may commonly
be found in tumours (Wardman, 1982).
The basic compound, Ro 03-8799, was
one of a series synthesized by Smithen et
at. (1980) In vitro studies showed a 10-fold
advantage over MISO as a radiosensitizer
but although improved sensitization has
been shown in vivo the factor has been
reduced to < 4 (Smithen et al., 1980).
This compound must be given i.v. since
after oral administration it is absorbed
slowly and then extensively metabolized
to the much less active N-oxide form.
After i.v. administration to mice, rats and
monkeys, there is a rapid clearance and a
high distribution volume which indicates
concentration within tissues, in contrast to
MISO which has a distribution volume
similar to that of the total body fluid
(Schwade et al., 1979).
MATERIALS AND METHODS
After the satisfactory administration of
small doses of 8-7, 44 and 87 mg to 2 normal
volunteers, the drug was administered to 6
patients with advanced malignancy who
presented areas of tumour which could be
biopsied. In all cases the informed consent of
the patients was obtained. Prior to adminis-
tration liver function tests in all cases yielded
normal results and renal function, as evi-RADIOSENSITIZER RO 03-8799 AND HUMAN TUMOURS
denced by the creatinine and urea levels, was
within normal limits.
Between 100 and 460 mg of [14C]-labelled
Ro 03-8799 was given i.v. bv slow infusion
over a 10 min period. Analyses of plasma,
red cells, tumour, urine, faeces and expired
air were made. The tumour samples were
taken at 30, 60 and 120 min after the
conclusion of the infusion except in case 6
where only one sample was taken at 30
min. A small representative portion of each
sample was sent for histological study as
established in our previous work with the
nitroimidazoles.
Quantities of Ro 03-8799 are reported as
free "base" and not as the HCI salt, the form
in which the drug is supplied. The types of
tumour and areas sampled are shown in
Table I.
RESULTS
No effect due to the drug was observed
after any one of the 10 administrations.
Subsequent serial haematological and bio-
chemical tests, including those of liver
function, failed to show any abnormality.
The drug was rapidly cleared from the
plasma after the i.v. infusion. A mean 2- 2
life of6-1 + 0-7 min (s.e.) was calculated for
the distribution phase and the elimination
2-life was 5-2 + 0-6 h giving values in
keeping with observations previously
made in animals. A study of 14C levels
showed that - 70% ofthe given dose was
excreted in the urine within 48 h part as
unchanged Ro 03-8799 but the majority in
altered form. Low levels of activity were
detected in the faeces and none in the
expired air. Red cell levels were 1-5-
2-0 x greater than those in the plasma
demonstrating the concentration in cells.
The pharmacokinetic data will be fully
















The amount of necrosis seen histologic-
ally in each representative portion was
expressed as a percentage of all tumour
seen. These values and the tumour levels
are shown in Table II together with the
plasma concentrations at the time of
sampling. The plasma and tumour concen-
trations in a representative case are shown
in the Figure.
DISCUSSION
In our previous work we have shown
that the concentration of MISO and
desmethylmisonidazole in a tumour sam-
ple is much influenced by the amount of
necrotic tissue present. This is well illus-
trated in case 2, where all the tumour
samples contained only trace levels of the
drug. Viable but hypoxic tumour cells
almost certainly appear normal on micro-
scopic examination. The concentration of
drug in necrotic tissue is irrelevant to the
purpose of radiosensitization. False im-
pressions as to the concentration of a
sensitizing drug in tumour tissue may,
therefore, be gained if the amount of
necrotic tissue in the sample is not
measured (Rich et al., 1981). In the
samples from cases 3, 5 and 6, little or no
necrotic tissue was present, and in all 3 a
high concentration of drug in tumour was
obtained. The mean tumour/plasma ratio
in the 7 samples obtained from these 3
patients is - 4:1. The Figure may be
unduly biased by one high ratio of 12:1
obtained in the analysis of the third
sample in case 5, and so a more realistic
figure for the tumour/plasma ratio may be
3:1.
High concentrations of [14C]-labelled
TABLE I.-Patients included in the study
Age Diagnosis Area of tumour sampling
70 Squamous cell carcinoma Ulcerated tumour encircling lower leg
of left leg
32 Mialignant melanoma Ulcerated mass of secondary glands right groin
71 Carcinoma of breast Discrete subcutaneous tumour nodules on trunk
71 Carcinoma of breast Ulcerated tumour replacing right breast
71 Carcinoma of breast Confluent tumour on chest wall
69 Malignant melanoma Subcutaneous metastasis near right shoulder
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material were found in tumour. When
expressed as jug/g equivalent of Ro 03-
8799 these levels were commonly 2-3 x
greater than the actual Ro 03-8799
concentrations. It would seem that meta-
bolism ofRo 03-8799 may occur within the
tumour cells. Alternatively, or in addition,
there could be some degradation of Ro 03-
8799 after removal of the tumour sample
before it can be frozen for despatch for
analysis. In this latter case the values
reported in Table II would be lower than
the levels of Ro 03-8799 present in the
tumours in vivo.
MISO is the radiosensitizing compound
which has been most extensively studied in
the laboratory and in the clinic. When 1 g
of MISO is given to a patient of average
size, the concentration in the plasma at the
time usually chosen for radiotherapy,
3-4 h after treatment, will be - 24 tig/ml.
With MISO the tumour concentration is,
on average, 80% of the plasma concentra-
tion, and so we can expect a level of
19,ig/g (Dische et al., 1981b).
From our observations with Ro 03-8799,
1 g ofthe pure base when administered will
give a plasma concentration of - 10 Htg/ml
at 30 min, the time when it would
probably be best to give radiotherapy.
From the observations we have made, we
can suggest that the concentration in
tumour at that time will be 30 ,tg/g. In
addition to the greater tumour concentra-
tion, Williams et al. (1982) concluded from
their work with tumours in mice that,
when tumour concentrations of Ro 03-
8799 and misonidazole are compared on a
molar basis, then Ro 03-8799 is 3 x as
effective as a sensitizer.
In the development of nitroimidazoles
as radiosensitizing drugs a great effort has
been made to find an animal system which
will predict the toxicity to be observed in
man. So far, no completely satisfactory
model has been found. The most reliable
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guidance has been obtained from toxico-
logical studies where there was daily
administration to animals over some
weeks; the most valuable observations
have been made in primates. With Ro 03-
8799, a 28-day i.v. toxicity study has been
undertaken in rats and cynomolgus mon-
keys by Roche Products Ltd (Eichler &
Jackson, personal communication, 1982).
In the monkeys, dose levels of the
hydrochloride salt were 50, 120 or 300
mg/kg/day for the first 10 days. At this
time, one animal in the high dose group
died and microscopic examination showed
acute hepatic damage: the dosage was
then reduced to 33, 80 and 200 mg/kg for
the remainder of the study. Some of the
animals given 300 mg/kg/day had shown
some hepatotoxicity at the end of 10 days,
as indicated by the results of function
tests, but these values, when repeated
after lowering the dose to 200 mg/kg/day,
showed a return to control levels. There
was no morphological evidence of hepatic
damage at the termination ofthe study. A
toxicological study using similar doses of
Ro 03-8799 has been performed in rats
without obvious hepatotoxicity. In the
monkeys, there was no adverse effect
noted on spermatogenesis but some saliva-
tion was noted in those receiving the
middle and high dose levels. Muscle tremor
and vomiting were observed occasionally
in the highest dose group ofmonkeys while
some locomotor disturbances lasting a few
minutes to several hours were seen in the
rats which were also in the highest dose
group.
These observations compare favourably
with those found with MISO when this
drug was also given by the i.v. route. With
a dose regime of 100 mg/kg/day severe
neurotoxicity was encountered (Eichler &
Jackson, personal communication, 1982).
The toxicological studies performed so
far would suggest that the tolerance of
man to Ro 03-8799 may prove to be twice
that of MISO.
Improved tolerance, higher concentra-
tion in tumour and greater radiosensitizing
efficiency may prove Ro 03-8799 to be a
considerable improvement as a radiosensi-
tizer when compared with misonidazole.
Only a full-scale study will determine,
however, whether this promise will be
achieved. The evidence is certainly encour-
aging and a more extensive administration
ofthe drug to man is being undertaken.
We wish to thank the Medical Research Council
for the Programme Grant supporting the clinical
work with radiosensitizers at Mount Vernon Hospital.
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